生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Bausch + Lomb
and
Modulight
Announce FDA Approval of ML6710i Photodynamic Laser for Use with
Bausch + Lomb
’s
VISUDYNE
® (
Verteporfin
for Injection)
2023-02-01
·
BioSpace
上市批准
VAUGHAN, Ontario & TAMPERE, Finland--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation (“Modulight”), a biomedical laser company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s
VISUDYNE
® (
verteporfin
for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic
subfoveal choroidal neovascularization
, or the creation of abnormal choroidal blood vessels, due to
Age-related Macular Degeneration (AMD).1
ML6710i is expected to be available for eye care professionals during the first half of 2023. “PDT continues to be an important treatment option for eye care professionals who are looking to treat patients with predominantly classic
subfoveal choroidal neovascularization
,” said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb. “With the approval of ML6710i, eye care professionals now have a new state-of-the-art photodynamic laser that addresses a significant unmet need in PDT and is specifically designed to deliver
VISUDYNE
to patients who suffer from
wet AMD
with persistent fluid.” ML6710i is a modern, easy-to-use and transportable ophthalmic laser that is controlled intuitively from an iPad mobile application. The laser’s beam shaping unit, which can be fit into all common slit lamps used for eye examinations, is formed into a circular, uniform spot to enable efficient treatment delivery of
VISUDYNE
. “As a result of our efforts with Bausch + Lomb, along with the feedback that many eye care professionals provided to our teams, we are thrilled to bring forward an innovative cloud connected laser platform that the ophthalmology community can use to deliver
VISUDYNE
to patients in need of treatment of
choroidal neovascularization
due to
AMD
,” said Seppo Orsila, founder and CEO, Modulight. About
VISUDYNE
VISUDYNE
is an injectable photosensitizer drug that is indicated for the treatment of patients with predominantly classic
subfoveal choroidal neovascularization
due to
AMD
,
pathologic myopia
or presumed ocular histoplasmosis.
VISUDYNE
is activated through use of a photodynamic laser via direct laser excitation, delivering a targeted approach that specifically destroys abnormal choroidal blood vessels to help prevent further disease progression and help patients maintain their vision.¹ INDICATION
VISUDYNE
(
verteporfin
for injection) therapy is indicated for the treatment of patients with predominantly classic
subfoveal choroidal neovascularization
due to
age-related macular degeneration
,
pathologic myopia
or presumed ocular histoplasmosis. IMPORTANT SAFETY INFORMATION
VISUDYNE
(
verteporfin
for injection) is contraindicated for patients with
porphyria
or known
hypersensitivity
to any component of this preparation. Standard precautions should be taken during infusion of
VISUDYNE
to avoid extravasation, including but not limited to: A free-flowing intravenous (IV) line should be established before starting
VISUDYNE
infusion and the line should be carefully monitored. Due to the possibly fragility of vein walls of some elderly patients, it is strongly recommended that the largest arm vein possible, preferably the antecubital, be used for injection. Small veins in the back of the hand should be avoided. Extravasation of
VISUDYNE
, especially if the affected area is exposed to light, can cause severe
pain
,
inflammation
,
swelling
or discoloration at the injection site. If extravasation does occur, the infusion should be stopped immediately. The extravasation area must be thoroughly protected from direct light until
swelling
and discoloration have faded in order to prevent the occurrence of
local burn
, which could be severe. Cold compresses should be applied to the injection site. Oral medication for
pain
relief may be administered. Following injection with
VISUDYNE
, care should be taken to avoid exposure of skin or eyes to direct sunlight or bright indoor light for 5 days. If emergency surgery is necessary within 48 hours after treatment, as much of the internal tissue as possible should be protected from intense light. Patients who experience severe decrease of vision of 4 lines or more within 1 week after treatment should not be retreated, at least until their vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered by the treating physician. The most frequently reported adverse events (occurring in approximately 10%-30% of patients) were
injection site reactions
(including
pain
,
edema
,
inflammation
,
extravasation
,
rashes
,
hemorrhage
, and discoloration), and
visual disturbances
(including blurred vision, flashes of light, decreased visual acuity, and visual field defects, including
scotoma
). Click here for full Prescribing Information. About Modulight Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company’s products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known
cancer
centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland. Its U.S. headquarters is in Palo Alto, CA. For more information, visit or follow Modulight on Twitter, LinkedIn, Facebook, YouTube and Instagram. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Twitter, LinkedIn, Facebook and Instagram. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving
COVID-19 pandemic
, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. References
VISUDYNE
[package insert], Bausch & Lomb Incorporated. VISUDYNE is a registered trademark of Cheplapharm Arzneimittel GmbH used under license. Any other product/brand names and/or logos are trademarks of the respective owners. © 2023 Bausch & Lomb Incorporated or its affiliates. VID.0006.USA.23
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Bausch & Lomb, Inc.
Modulight Oy
适应症
脉络膜新生血管
年龄相关性黄斑变性1型
黄斑变性
[+17]
靶点
-
药物
维替泊芬
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务